Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Opus Genetics (IRD) Short-Term Debt repayments (2021 - 2022)

Opus Genetics (IRD) reported Short-Term Debt repayments of $215000.0 for Q2 2022, down 33.44% on a QoQ basis from $323000.0 in Q1 2022.

Opus Genetics (IRD) has 2 years of Short-Term Debt repayments data on file, last reported at $215000.0 in Q2 2022.

  • Quarterly Short-Term Debt repayments changed N/A year-over-year to $215000.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $215000.0 (down 50.12% YoY) and the FY2022 annual result came in at $538000.0, up 398.15% from the prior year.
  • Short-Term Debt repayments eased to $215000.0 in Q2 2022 per IRD's latest filing, from $323000.0 in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $323000.0 in Q1 2022 and bottomed at $108000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 102,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Opus Genetics 357.99 Mn 298.03 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 215,000.00
Jun 30, 2022 215,000.00
Mar 31, 2022 323,000.00
Mar 31, 2022 323,000.00
Dec 31, 2021 108,000.00
Dec 31, 2021 108,000.00